Outcomes of neoadjuvant chemoradiotherapy followed by radical resection for T4 colorectal cancer.

Background: Patients with clinical T4 colorectal cancer (CRC) have a poor prognosis because of compromised surgical margins. Neoadjuvant therapy may be effective in downstaging tumors, thereby rendering possible radical resection with clear margins.

Aim: To evaluate tumor downsizing and resection with clear margins in T4 CRC patients undergoing neoadjuvant concurrent chemoradiotherapy followed by surgery.

Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.

Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC. Herein, we present 6 consecutive patients with mCRC combined with hyperbilirubinemia who underwent UGT1A1 genotyping before receiving FOLFIRI plus bevacizumab. Dose escalation of irinotecan was performed according to the results of UGT1A1 genotyping in all patients.

High expression of phospho-H2AX predicts a poor prognosis in colorectal cancer.

Background/aim: Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths worldwide. DNA double-strand breaks (DSBs) are deleterious lesions that can lead to chromosomal anomalies, genomic instability and cancer. The histone H2AX plays an important role in response to DNA damage and phosphorylation of H2AX (p-H2AX) is evidence of DSBs.

The effect of portal hypertension on the glycoprotein biosynthesis of rat gastric mucosa.

The aim of this study was to assess the influence of epidermal growth factor (EGF) on glycoprotein biosynthesis in portal hypertensive (PHT) gastric mucosa. Portal-vein ligation (PVL) for a period of 4 weeks was applied to 40 male Wistar rats to produce experimental portal hypertension. The rats were subdivided into four groups.

Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients.

To assess the prevalence and spectrum of K-ras mutations in Taiwanese patients with pancreatic adenocarcinoma, we analyzed 20 patients of ductal adenocarcinoma of the head of the pancreas undergoing pancreaticoduodenectomy. The study included K-ras mutations that were detected using DNA direct sequencing analysis of the polymerase chain reaction products and confirmed by reverse sequencing primers. The results showed that K-ras codon 12 mutation was detected in 90% of the cancer tissues (18/20).